Literature DB >> 14662730

A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Aram Elagoz1, Duncan Henderson, Poda Suresh Babu, Sylvia Salter, Caroline Grahames, Lorna Bowers, Marie-Odile Roy, Patricia Laplante, Eric Grazzini, Sultan Ahmad, Paola M C Lembo.   

Abstract

1. Human formyl peptide-receptor-like-1 (FPRL-1) is a promiscuous G protein-coupled receptor (GPCR), and belongs to a chemoattractant receptor family protein. This receptor has been reported to interact with various host-derived peptides and lipids involved in inflammatory responses. We described here, a novel role for FPRL-1 as a high-affinity beta-chemokine receptor for an N-terminally truncated form of the CKbeta8 (CCL23/MPIF-1) splice variant CKbeta8-1 (22-137 aa). 2. RT-PCR analysis of mRNA derived from human tissues and cells revealed a predominant expression of FPRL-1 in inflammatory cells, particularly in neutrophils. 3. Intracellular calcium mobilisation assay, used as screening tool, in recombinant Chinese hamster ovary (CHO-K1) and human embryonic kidney (HEK293s) cells coexpressing FPRL-1 and Galpha(16), demonstrated FPRL-1 is a functional high-affinity receptor for CKbeta8-1 (46-137 aa, sCKbeta8-1), with pEC(50) values of 9.13 and 8.85, respectively. 4. The FPRL-1 activation in CHO-K1 cells is mediated by Galpha(i)/Galpha(o) proteins, as assessed by pertussis toxin sensitivity and inhibition of forskolin-induced cyclic AMP accumulation. 5. Binding experiments were performed with a radio-iodinated synthetic peptide, [(125-)I]-WKYMVm, a known potent FPRL-1 agonist. CHO-K1 cell membranes expressing FPRL-1 bound [(125-)I]-WKYMVm with a K(d) value of 9.34. Many known FPRL-1 agonists were tested and sCKbeta8-1 was the most effective nonsynthetic ligand in displacing the radiolabelled agonist, with a pIC(50) of 7.97. 6. The functional significance of sCKbeta8-1 interaction with FPRL-1 was further demonstrated by the activation of polymorphonuclear leukocytes (PMNs) calcium mobilisation and chemotaxis. These interactions were shown to be via FPRL-1 by specific blockade of PMNs activation in the presence of an FPRL-1 antibody.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662730      PMCID: PMC1574175          DOI: 10.1038/sj.bjp.0705592

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways.

Authors:  B E Hawes; E Kil; B Green; K O'Neill; S Fried; M P Graziano
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

2.  Expression of functional formyl peptide receptors by human astrocytoma cell lines.

Authors:  Y Le; J Hu; W Gong; W Shen; B Li; N M Dunlop; D O Halverson; D G Blair; J M Wang
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

Review 3.  Pleiotropic roles of formyl peptide receptors.

Authors:  Y Le; J J Oppenheim; J M Wang
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

4.  Characterization of CKbeta8 and CKbeta8-1: two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1.

Authors:  B S Youn; S M Zhang; H E Broxmeyer; S Cooper; K Antol; M Fraser; B S Kwon
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

5.  Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor.

Authors:  P Proost; S Struyf; M Couvreur; J P Lenaerts; R Conings; P Menten; P Verhaert; A Wuyts; J Van Damme
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

6.  CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.

Authors:  B J Votta; J R White; R A Dodds; I E James; J R Connor; E Lee-Rykaczewski; C F Eichman; S Kumar; M W Lark; M Gowen
Journal:  J Cell Physiol       Date:  2000-05       Impact factor: 6.384

7.  Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils.

Authors:  S S Cheng; J J Lai; N W Lukacs; S L Kunkel
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

8.  Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.

Authors:  J Vakili; L Ständker; M Detheux; G Vassart; W G Forssmann; M Parmentier
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

9.  The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.

Authors:  T Christophe; A Karlsson; C Dugave; M J Rabiet; F Boulay; C Dahlgren
Journal:  J Biol Chem       Date:  2001-04-02       Impact factor: 5.157

10.  Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.

Authors:  N Chiang; I M Fierro; K Gronert; C N Serhan
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  18 in total

Review 1.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

2.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

3.  Generation of High-Specificity Antibodies against Membrane Proteins Using DNA-Gold Micronanoplexes for Gene Gun Immunization.

Authors:  Debra T Hansen; Felicia M Craciunescu; Petra Fromme; Stephen A Johnston; Kathryn F Sykes
Journal:  Curr Protoc Protein Sci       Date:  2018-02-21

4.  Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus.

Authors:  Dorothee Kretschmer; Anne-Kathrin Gleske; Maren Rautenberg; Rong Wang; Martin Köberle; Erwin Bohn; Torsten Schöneberg; Marie-Joséphe Rabiet; Francois Boulay; Seymour J Klebanoff; Kok A van Kessel; Jos A van Strijp; Michael Otto; Andreas Peschel
Journal:  Cell Host Microbe       Date:  2010-06-25       Impact factor: 21.023

5.  Transcriptional variations mediated by an alternative promoter of the FPR3 gene.

Authors:  Hong-Seok Ha; Jae-Won Huh; Jeong-An Gim; Kyudong Han; Heui-Soo Kim
Journal:  Mamm Genome       Date:  2011-06-30       Impact factor: 2.957

Review 6.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

Review 8.  The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.

Authors:  R Colobran; R Pujol-Borrell; M P Armengol; M Juan
Journal:  Clin Exp Immunol       Date:  2007-10       Impact factor: 4.330

Review 9.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

10.  Yellow fluorescent protein-based assay to measure GABA(A) channel activation and allosteric modulation in CHO-K1 cells.

Authors:  Teres Johansson; Tyrrell Norris; Helena Peilot-Sjögren
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.